Literature DB >> 7420088

Motor neurone disease with elevated cerebrospinal fluid protein.

R J Guiloff, B McGregor, E Thompson, W Blackwood, E Paul.   

Abstract

The correlation between age and CSF protein in 38 patients with pathologically proven motor neurone disease was the reverse of that described for normal subjects by Tibbling et al in 1977. Eight had CSF protein ranging from 0.75 g/1 to 1.52 g/L. These patients were younger, but other clinical and gross and light microscopy pathological features were not significantly different from those with lower CSF protein. Transudation from serum may be only one of the mechanisms underlying this elevation in CSF protein.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7420088      PMCID: PMC490564          DOI: 10.1136/jnnp.43.5.390

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  [Limitations of paper electrophoretic determination of blood & CSF proteins in neurological & psychiatric diseases].

Authors:  P SARTESCHI; P FABIANI
Journal:  Rass Studi Psichiatr       Date:  1956

2.  A micro biuret method for protein determination; determination of total protein in cerebrospinal fluid.

Authors:  J GOA
Journal:  Scand J Clin Lab Invest       Date:  1953       Impact factor: 1.713

3.  The diagnostic value of the examination of the cerebrospinal fluid.

Authors:  J N CUMINGS
Journal:  Postgrad Med J       Date:  1952-11       Impact factor: 2.401

4.  Amyotrophic lateral sclerosis.

Authors:  T LAWYER; M G NETSKY
Journal:  AMA Arch Neurol Psychiatry       Date:  1953-02

5.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

6.  Motor neurone disease as a manifestation of neoplasm (with a note on the course of classical motor neurone disease).

Authors:  L Brain; P B Croft; M Wilkinson
Journal:  Brain       Date:  1965-09       Impact factor: 13.501

7.  Serum-CSF protein gradients, the blood-GSF barrier and the local immune response.

Authors:  G Schliep; K Felgenhauer
Journal:  J Neurol       Date:  1978-05-18       Impact factor: 4.849

8.  Patient resistance and prognosis in amyotrophic lateral sclerosis.

Authors:  D W Mulder; F M Howard
Journal:  Mayo Clin Proc       Date:  1976-09       Impact factor: 7.616

9.  Isoelectric focusing and electrophoresis of cerebrospinal fluid proteins in muscular dystrophies and spinal muscular atrophies.

Authors:  K G Kjellin; H Stibler
Journal:  J Neurol Sci       Date:  1976-01       Impact factor: 3.181

10.  [Amyotrophic lateral sclerosis occuring befor the age of 40 years. Remarks apropos of 25 cases].

Authors:  G Aimard; B Bady; D Boisson; P Trouillas; M Devic
Journal:  Rev Neurol (Paris)       Date:  1976-08       Impact factor: 2.607

View more
  8 in total

Review 1.  Immunology of amyotrophic lateral sclerosis.

Authors:  N R Cashman; M E Gurney; J P Antel
Journal:  Springer Semin Immunopathol       Date:  1985

2.  SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

Authors:  Leah Winer; Dushyanth Srinivasan; Seung Chun; David Lacomis; Matthew Jaffa; Anne Fagan; David M Holtzman; Ed Wancewicz; C Frank Bennett; Robert Bowser; Merit Cudkowicz; Timothy M Miller
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

3.  Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease.

Authors:  R J Guiloff; D J Eckland; C Demaine; R C Hoare; K D MacRae; S L Lightman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

4.  Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis.

Authors:  A Leonardi; G Abbruzzese; L Arata; L Cocito; M Vische
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

5.  Motor neuron disease with multi-system involvement presenting as tetraparesis, ophthalmoplegia and sensori-autonomic dysfunction.

Authors:  S Takeda; M Yamada; K Kawasaki; K Oyanagi; F Ikuta; M Arai; T Inuzuka; N Yuki; T Yuasa; S Sato
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

6.  Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis.

Authors:  J Saul; E Hutchins; R Reiman; M Saul; L W Ostrow; B T Harris; K Van Keuren-Jensen; R Bowser; N Bakkar
Journal:  Acta Neuropathol Commun       Date:  2020-06-26       Impact factor: 7.801

7.  Elevated Cerebrospinal Fluid Proteins and Albumin Determine a Poor Prognosis for Spinal Amyotrophic Lateral Sclerosis.

Authors:  Abdelilah Assialioui; Raúl Domínguez; Isidro Ferrer; Pol Andrés-Benito; Mónica Povedano
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

8.  Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis.

Authors:  Ethan A Winkler; Jesse D Sengillo; John S Sullivan; Jenny S Henkel; Stanley H Appel; Berislav V Zlokovic
Journal:  Acta Neuropathol       Date:  2012-09-01       Impact factor: 17.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.